Navigation Links
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
Date:10/25/2012

HILDEN, Germany, October 25, 2012 /PRNewswire/ --

  • QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine
  • The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare
  • Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient's tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

"We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. "The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics ba
'/>"/>

SOURCE Qiagen N V
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
6. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. AspenBio to Present at 2012 Aegis Healthcare Conference
9. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
10. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
11. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... water from their roots up to their leaves hundreds of ... at the University of Rochester have created a simple slab ... so at a speed that would make nature envious. , ... Physics Letters , may prove invaluable in pumping microscopic amounts ...
... , SAN DIEGO, June 2 Optimer Pharmaceuticals, Inc. ... from its North American Phase 3 clinical study of ... (CDI) were presented today by clinical investigator, Mark A. ... in Chicago. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ...
... College Troy campus to ... , TROY, Mich., June 2 Walsh College and ... offer a new series of Walsh College,s successful "Take Charge" workshops for the ... more topics and expanded career content. All are provided at no cost ...
Cached Biology Technology:Scientists create metal that pumps liquid uphill 2Scientists create metal that pumps liquid uphill 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 2Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 3Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 4
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle East ... estimates and forecasts are provided for the period 2013 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... can drastically affect the habitability of marine ecosystems, according ... the expansion and contraction of low-oxygen zones in the ... by assistant professor of atmospheric and oceanic sciences Curtis ... the first time that the size of low-oxygen zones ...
... Avoiding germs to prevent sickness is commonplace for ... are among the tips humans learn. But plants, ... it alone. They grow where planted, in an environment ... scientists note. Now, researchers are learning from plants, ...
... The largest fire in the history of the state of ... using satellite data from a variety of instruments to plan ... are out. The Landsat 5 satellite captured images ... eastern Arizona on June 15, 2011 at 19:54:23 Zulu (3:54 ...
Cached Biology News:Ocean's harmful low-oxygen zones growing, are sensitive to small changes in climate 2Ocean's harmful low-oxygen zones growing, are sensitive to small changes in climate 3Plants teach humans a thing or two about fighting diseases 2Landsat 5 satellite helps emergency managers fight largest fire in Arizona history 2
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
... Researchers no longer need to perform time consuming ... With Mutation Surveyor, any found variants of the ... clearly indicated in our mutation electropherogram as a ... the bi-directional analysis mode is over 99%, with ...
... 220-240 V, is used for biolistic particle delivery ... an adjustable helium pulse to sweep DNA-, RNA-, ... wall of a small plastic cartridge directly into ... in situ, in vitro, in vivo, and ex ...
Biology Products: